Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients

ConclusionSGLT2 inhibitor DAPA was associated with lower risks of incident AKI and all-cause mortality in AMI patients after PCI therapy.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research